Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 101

1.

Reduced price on rotavirus vaccines: enough to facilitate access where most needed?

Madsen LB, Ustrup M, Fischer TK, Bygbjerg IC, Konradsen F.

Bull World Health Organ. 2012 Jul 1;90(7):554-6. doi: 10.2471/BLT.11.094656. No abstract available.

2.

The promise of immunisation against rotavirus.

Marlow RD, Finn A.

Arch Dis Child. 2012 Aug;97(8):736-40. doi: 10.1136/archdischild-2011-301472. Epub 2012 May 18. Review.

PMID:
22611059
3.

Should rotavirus vaccines be included in the national immunization program of a small developed country?

Milne R, Grimwood K.

Expert Rev Pharmacoecon Outcomes Res. 2009 Oct;9(5):401-4. doi: 10.1586/erp.09.46. No abstract available.

PMID:
19817522
4.

Rotavirus vaccines: targeting the developing world.

Glass RI, Bresee JS, Turcios R, Fischer TK, Parashar UD, Steele AD.

J Infect Dis. 2005 Sep 1;192 Suppl 1:S160-6.

5.

Evaluation of potential medical and economic benefits of universal rotavirus vaccination in Greece.

Syriopoulou V, Kafetzis D, Theodoridou M, Syrogiannopoulos GA, Mantagos S, Trimis G, Mavrikou M, Konstantopoulos A.

Acta Paediatr. 2011 May;100(5):732-9. doi: 10.1111/j.1651-2227.2010.02127.x. Epub 2011 Jan 12.

PMID:
21223372
6.

Cost-effectiveness of introducing a rotavirus vaccine in developing countries: the case of Mexico.

Valencia-Mendoza A, Bertozzi SM, Gutierrez JP, Itzler R.

BMC Infect Dis. 2008 Jul 29;8:103. doi: 10.1186/1471-2334-8-103.

7.

Projected health and economic impact of rotavirus vaccination in GAVI-eligible countries: 2011-2030.

Atherly DE, Lewis KD, Tate J, Parashar UD, Rheingans RD.

Vaccine. 2012 Apr 27;30 Suppl 1:A7-14. doi: 10.1016/j.vaccine.2011.12.096.

PMID:
22520139
8.

Potential impact and cost-effectiveness analysis of rotavirus vaccination of children in Israel.

Chodick G, Waisbourd-Zinman O, Shalev V, Kokia E, Rabinovich M, Ashkenazi S.

Eur J Public Health. 2009 Jun;19(3):254-9. doi: 10.1093/eurpub/ckp005. Epub 2009 Feb 12.

9.

Economic analysis for evidence-based policy-making on a national immunization program: a case of rotavirus vaccine in Thailand.

Muangchana C, Riewpaiboon A, Jiamsiri S, Thamapornpilas P, Warinsatian P.

Vaccine. 2012 Apr 16;30(18):2839-47. doi: 10.1016/j.vaccine.2012.02.047. Epub 2012 Mar 2.

PMID:
22387220
10.

Health and economic impact of rotavirus vaccination in GAVI-eligible countries.

Kim SY, Sweet S, Slichter D, Goldie SJ.

BMC Public Health. 2010 May 14;10:253. doi: 10.1186/1471-2458-10-253.

11.

Health economics of rotavirus immunization in Vietnam: potentials for favorable cost-effectiveness in developing countries.

Tu HA, Rozenbaum MH, Coyte PC, Li SC, Woerdenbag HJ, Postma MJ.

Vaccine. 2012 Feb 14;30(8):1521-8. doi: 10.1016/j.vaccine.2011.11.052. Epub 2011 Nov 23.

PMID:
22119590
12.

Distributional impact of rotavirus vaccination in 25 GAVI countries: estimating disparities in benefits and cost-effectiveness.

Rheingans R, Atherly D, Anderson J.

Vaccine. 2012 Apr 27;30 Suppl 1:A15-23. doi: 10.1016/j.vaccine.2012.01.018.

PMID:
22520124
13.

Public health. Progress toward rotavirus vaccines.

Parashar UD, Glass RI.

Science. 2006 May 12;312(5775):851-2. No abstract available.

PMID:
16690845
14.

Outstanding challenges for rotavirus vaccine introduction in low-income countries--a systematic review.

Ustrup M, Madsen LB, Bygbjerg IC, Konradsen F.

Dan Med Bull. 2011 Oct;58(10):A4323. Review.

PMID:
21975154
15.

Rotavirus vaccination in developing countries.

Babji S, Kang G.

Curr Opin Virol. 2012 Aug;2(4):443-8. doi: 10.1016/j.coviro.2012.05.005. Epub 2012 Jun 13. Review.

PMID:
22698800
16.

Should India launch a national immunisation programme against rotavirus? Yes.

Rose J, Parashar UD.

BMJ. 2012 Nov 30;345:e7818. doi: 10.1136/bmj.e7818. No abstract available.

PMID:
23203999
17.

Lessons from the US rotavirus vaccination program.

Glass RI, Patel M, Parashar U.

JAMA. 2011 Oct 19;306(15):1701-2. doi: 10.1001/jama.2011.1475. No abstract available.

PMID:
22009102
18.

Cost-effectiveness of a pentavalent human-bovine reassortant rotavirus vaccine for children ≤5 years of age in Taiwan.

Itzler RF, Chen PY, Lac C, El Khoury AC, Cook JR.

J Med Econ. 2011;14(6):748-58. doi: 10.3111/13696998.2011.614303. Epub 2011 Sep 15.

PMID:
21919673
19.

Costs of diarrheal disease and the cost-effectiveness of a rotavirus vaccination program in kyrgyzstan.

Flem ET, Latipov R, Nurmatov ZS, Xue Y, Kasymbekova KT, Rheingans RD.

J Infect Dis. 2009 Nov 1;200 Suppl 1:S195-202. doi: 10.1086/605040.

20.

Insights from global data for use of rotavirus vaccines in India.

Rao TS, Arora R, Khera A, Tate JE, Parashar U, Kang G; Indian Rotavirus Vaccine Working Group.

Vaccine. 2014 Aug 11;32 Suppl 1:A171-8. doi: 10.1016/j.vaccine.2014.03.029. Review.

Items per page

Supplemental Content

Write to the Help Desk